Format

Send to

Choose Destination
ACS Chem Neurosci. 2011 Apr 20;2(4):183-4. doi: 10.1021/cn200023v.

ACS chemical neuroscience molecule spotlight on Qnexa.

Author information

1
Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy , One University Park Drive, Nashville, Tennessee 37204, United States.

Abstract

Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical trials for the treatment of obesity. Vivus, Inc. has demonstrated efficacy of their product and are currently addressing FDA safety concerns with the possibility of a New Drug Application (NDA) resubmission.

KEYWORDS:

Qnexa; obesity; phentermine; topiramate; weight-loss

PMID:
22778866
PMCID:
PMC3369742
DOI:
10.1021/cn200023v
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center